Zacks.com on MSN6 小时
Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold?
Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 35.6% in the past six months compared with the industry’s decline ...
Too Old to Operate7 小时
Benralizumab Improves Outcomes in Acute Eosinophilic Exacerbations
The following is a summary of “Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial,” published in ...
manilatimes8 小时
Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd ...
EYLEA HD® and EYLEA® remained the U.S. anti-VEGF category leader in 2024; aggregate U.S. net product sales were $6 billion for full-year 2024, up 1% based on preliminary (unaudited) results EYLEA HD ...